Impact of a novel nutritional formula on asthma control and biomarkers of allergic airway inflammation in children
Impact of a novel nutritional formula on asthma control and biomarkers of allergic airway inflammation in children
复制标题
DOI：
10.1111/j.1365-2222.2010.03523.x
复制
发表时间：
2010-08-01
影响因子：
6.1
通讯作者：
Szefler, S. J.
中科院分区：
文献类型：
--
作者：
Covar, R.;Gleason, M.;Szefler, S. J.
P>背景一种富含二十碳五烯酸（EPA）和γ-亚麻酸脂肪酸和抗氧化剂的新型营养配方（NNF）可减少气道炎症并改善危重患者的临床结果，但NNF尚未在持续性哮喘等慢性炎症性疾病中进行评估。目的评估NNF在哮喘儿童中的疗效、依从性和安全性。方法6-14岁患有轻至中度持续性哮喘的儿童按需单独服用沙丁胺醇，随机接受每日 NNF (n = 23) 或对照配方奶粉 (n = 20)，持续 12 周，并对哮喘控制、肺量测定、气道炎症测量、配方奶粉耐受性和不良事件进行多项评估。结果随着时间的推移，每日食用 NNF 或对照配方奶粉显示无哮喘天数有所改善 (P = 0.04)，但组间没有差异。然而，与对照组相比，NNF 组在第 4、8 和 12 周时呼出一氧化氮水平较低（P < 0.05）。 log FEV1 PC20 的总体组间差异（P=0.05）也有利于 NNF 组。两周内，与对照组相比，NNF 组血浆中 EPA (P < 0.01) 和外周血单核细胞 (PBMC) (P < 0.01) 磷脂水平显着升高，表明每日 NNF 摄入的依从性良好。 12 周后，NNF 组与对照组的不良事件没有差异。结论 NNF 组和对照组的无哮喘天数均有所改善。 NNF 治疗组的疾病活动性生物标志物减少。 PBMC 脂肪酸组成的快速变化反映了抗炎特性。膳食补充剂 NNF 是安全且耐受性良好的（ClinicalTrials.gov 编号 NCT01087710）。引用：R. Covar、M. Gleason、B. Macomber、L. Stewart、P. Szefler、K. Engelhardt、J. Murphy、A. Liu、S. Wood、S. DeMichele、E. W. Gelfand 和 S. J. Szefler，临床与实验过敏，2010（40）1163-1174。
P>BackgroundA novel nutritional formula (NNF) enriched in eicosapentaenoic (EPA) and gamma-linolenic fatty acids and antioxidants reduces airway inflammation and improves clinical outcomes in critically ill patients, but NNF has not been evaluated in chronic inflammatory diseases such as persistent asthma.ObjectiveTo evaluate the efficacy, compliance, and safety of NNF in asthmatic children.MethodsChildren, 6-14 years of age, with mild to moderate persistent asthma, on as needed albuterol alone, were randomized to receive daily NNF (n=23) or control formula (n=20) for 12 weeks, with multiple assessments of asthma control, spirometry, measures of airway inflammation, formula tolerance, and adverse events.ResultsDaily consumption of either NNF or a control formula showed improvement in asthma-free days over time (P=0.04) but there was no difference between groups. However, the NNF group had lower exhaled nitric oxide levels compared with the control group at weeks 4, 8, and 12 (P < 0.05). An overall group difference in log FEV1 PC20 (P=0.05) was found in favour of the NNF group as well. Significantly higher levels of EPA in plasma (P < 0.01) and peripheral blood mononuclear cell (PBMC) (P < 0.01) phospholipids in the NNF group compared with control group within 2 weeks indicated good adherence with daily NNF intake. There were no differences in adverse events for NNF vs. control after 12 weeks.ConclusionsBoth NNF and control groups demonstrated improvement in asthma-free days. NNF-treated group had reduced biomarkers of disease activity. Rapid PBMC fatty acid composition changes reflected an anti-inflammatory profile. Dietary supplementation with NNF was safe and well tolerated (ClinicalTrials.gov number NCT01087710).Cite this as: R. Covar, M. Gleason, B. Macomber, L. Stewart, P. Szefler, K. Engelhardt, J. Murphy, A. Liu, S. Wood, S. DeMichele, E. W. Gelfand and S. J. Szefler, Clinical & Experimental Allergy, 2010 (40) 1163-1174.